Skip to main content
. 2019 Aug 27;8:e43668. doi: 10.7554/eLife.43668

Figure 1. Engineering and validation of a novel genetically engineered mouse model of BRAFV600E driven cancer.

(A) The BrafCAT mouse builds upon the utility of the BrafCA mouse by tying expression of the oncogenic form of BRAF to expression of the red fluorescent protein, tdTomato. (B) Targeted BrafCAT ES cells display membrane associated red fluorescence only after the addition of TAT-CRE. (C) Comparison of Ad-CMV-CRE initiated lung tumor formation and fluorescence in frozen sections from lungs of BrafCAT/+ and BrafCA/+ animals. (D) Lung adenoma found in a BrafCAT animal showing fluorescence in the tumor (arrowhead) and not in the lung parenchyma (asterisk).

Figure 1.

Figure 1—figure supplement 1. Engineering and validation of a novel genetically engineered mouse model of BRAFV600E driven cancer.

Figure 1—figure supplement 1.

(A) Lung adenoma found in a BrafCA animal showing no specific fluorescence in the tumor. (B) BrafCAT MEFs display detectable red fluorescence within 24 hr of Ad-CMV-CRE addition, with the majority of cells displaying red fluorescence within 72 hr.